MediPharm Labs Acquires Large Volumes of Dried Cannabis for Oil Extraction Ensuring Continuous Product Supply

TORONTO, Jan. 10, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSXV: LABS; OTCQB: MLCPF) (the “Company” or “MediPharm Labs”), a specialized, research-driven cannabis extraction business, fully licensed under the Cannabis Act (Canada) focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc. (“MediPharm”), has secured large volumes of dried cannabis inventory for oil extraction and resale. MediPharm purchased over 1,600 kg of additional dried cannabis from 7 different licensed producers between December 18, 2018 and January 8, 2019, replenishing and increasing inventory to ensure uninterrupted cannabis oil supply for its existing customers for Q1 2019 and to satisfy the robust and growing market demand for high quality purified concentrates. MediPharm also continues to receive large quantities of dried cannabis for fee-for-service processing from its Cannabis Concentrate Program Agreement partners.

In 2019 we have continued to build momentum. We are ramping up production and building inventory to increase oil sales and accelerate revenue expectations.

Mr. Pat McCutcheon, President & CEO, MediPharm Labs

With large volumes of dried cannabis secured, MediPharm is positioned to deliver on our customers’ expectations for uninterrupted near-term oil supply while also increasing overall oil inventory to start addressing the existing significant market demand for concentrates that continues to grow at an exponential pace.

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from its cGMP (current Good Manufacturing Practices) and ISO standard-built clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand. In addition, MediPharm Labs will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products. MediPharm Labs was awarded Start-Up Of The Year at the recent Canadian Cannabis Awards hosted by Lift & Co.

Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.

Original Press Release

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter